As per the publication of August 2020, entitled "Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry", this has been demonstrated that out of the total subjects considered under study 64.1% relied on adalimumab therapy for 1 year and 10.2% relied on more than 12 years. The patients reported had the mean age of 53.9 years or more than that.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-adalimumab-market
Global adalimumab market is expected to reach USD 28,508.07 million by 2027 from USD 19,905.00 million in 2019, growing with the CAGR of 4.8% in the forecast period of 2020 to 2027. The demand for adalimumab has been increased in both developed well as in developing countries and the reason behind this is the rise in the prevalence of inflammatory autoimmune diseases. The adalimumab market is growing due to the growing geriatric population and an increasing number of contract research organizations. The market will grow in the forecasted period due to the presence of product pipeline, strategic initiatives by market players, and increasing healthcare expenditure among others.
Increasing prevalence of rheumatoid arthritis across the world will drive the market's growth rate
The prevalence of rheumatoid arthritis is increasing worldwide and this has been reported that globally, the annual incidence of RA is nearly 3 cases per 10,000 populations. Rheumatoid arthritis leads to development of inflammatory symptoms which can be treated by several drug therapies involving biological therapies, among others. One of the most innovative biological therapy discovered for treatment of rheumatoid arthritis includes adalimumab, a monoclonal antibody which targets the immune cells ad slows down the recruitment of immune cells that leads to decrease the inflammation at target site. Rheumatoid arthritis is one of the chronic diseases and has become the worldwide healthcare concern. The changes in lifestyle pattern, physical inactivity and increasing geriatric population are some factors responsible for increasing the prevalence of rheumatoid arthritis.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2020 to 2027
|
Base Year
|
2019
|
Historic Years
|
2018 (Customizable to 2013 - 2018)
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
Segments Covered
|
Drug class (Antirheumatics, TNF Alfa Inhibitors, Others), Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Non-Infectious Intermediate, Others), Type (Biologics, Biosimilars), Dosage Strength (40mg/0.4mlg, 80mg/0.8mlg, 20mg/0.2mlg, 10mg/0.1mlg, Others), Drug Type (Branded, Generics), Route of Administration (Oral, Parenteral, Others), Age Group (Pediatric, Adult, Geriatric), Dosage Form (Tablet, Injection, Solution, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
Countries Covered
|
U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Biogen (U.S.), Fresenius Kabi AG (Germany), Boehringer Ingelheim International GmbH. (Germany), Amgen Inc. (U.S.), AbbVie Inc. (U.S.), Abbott (U.S.), CELLTRION INC. (South Korea), Samsung Bioepis (South Korea), Coherus BioSciences (U.S.), Innovent Biologics, Inc. (China), Hetero Biopharma Ltd. (India), Reliance Life Sciences (India) among others.
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
Global adalimumab market is categorized into eight notable segments which are indication, type, dosage strength, drug type, route of administration, population type, end user and distribution channel.
The hospitals segment will dominate the end user segment of the adalimumab market
The hospitals segment will emerge as the dominating segment end user segment. This is because of the growing number of hospitals in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.
The hospital pharmacies segment will dominate the distribution channel segment of the adalimumab market
The hospital pharmacies segment will emerge as the dominating segment under distribution channel. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in market: F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Biogen (U.S.), Fresenius Kabi AG (Germany), Boehringer Ingelheim International GmbH. (Germany), Amgen Inc. (U.S.), AbbVie Inc. (U.S.), Abbott (U.S.), CELLTRION INC. (South Korea), Samsung Bioepis (South Korea), Coherus BioSciences (U.S.), Innovent Biologics, Inc. (China), Hetero Biopharma Ltd. (India), Reliance Life Sciences (India).
Market Development
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
As per Data Bridge Market Research analysis:
North America is the dominant region in adalimumab market during the forecast period 2020 - 2027
North America dominates the adalimumab market because of the growing geriatric population and surging prevalence of rheumatoid arthritis in this region. Additionally the rising healthcare expenditure will further propel the market's growth rate in this region.
Asia-Pacific is estimated to be the fastest-growing region in adalimumab market the forecast period 2020 - 2027
Asia-Pacific are expected to grow during the forecast period due to surging focus for the development of generic and biosimilar products and the increasing number of geriatric population in this region. Also, development of healthcare infrastructure will further propel the market's growth rate in this region.
COVID-19 Impact
The cause of the pneumonia cases was determined to be COVID-19, a brand-new coronavirus. The rapid global spread of this virus resulted in a significant number of fatalities. The World Health Organization (WHO) declared COVID-19 a global pandemic in March 2020 and advised strict action to stop the disease's spread. Since then, the pandemic has slowed down healthcare industry growth and hampered the supply chain. To stop the spread of COVID-19, governments in several countries have enacted nationwide lockdowns. Similar issues prevented healthcare firms around the world from carrying out their supply chain operations. The slowness of the supply chain restricted the market for adalimumab.
For more detailed information about the adalimumab market, visit: https://www.databridgemarketresearch.com/reports/global-adalimumab-market
Global Adalimumab Market – Industry Trends and Forecast to 2029
Asia-Pacific Adalimumab Market – Industry Trends and Forecast to 2030
North America Adalimumab Market – Industry Trends and Forecast to 2030
Europe Adalimumab Market – Industry Trends and Forecast to 2029
Middle East and Africa Adalimumab Market – Industry Trends and Forecast to 2029
AbbVie Inc., Amgen Inc., and Biogen were dominating Europe Adalimumab Market in 2021